COMMUNIQUÉS West-GlobeNewswire

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
22/09/2026
New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or [...]
Clene to Present at Upcoming Investor Conferences
22/09/2026
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5 th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners [...]
Envisagenics and Boehringer Ingelheim Enter Multi-Target Collaboration to Develop First-in-Class Precision Therapies Based on RNA Splicing-Derived Targets for Hard-to-Treat Cancers
22/09/2026
Envisagenics’ AI-powered SpliceCore ® platform opens up alternative RNA splicing – one of the last largely untapped sources of tumor-specific targets – for precision oncology Boehringer Ingelheim may apply selected [...]
Adventist Health Bakersfield Introduces Kern County’s First Next Generation Robotic-Assisted Bronchoscopy
22/09/2026
Advanced technology helps physicians detect lung cancer earlier and improve treatment BAKERSFIELD, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Kern County and surrounding areas now have access to a next-generation, [...]
Medera Expands Singapore Presence Through Partnership with National Heart Centre Singapore
22/09/2026
Medera establishes Singapore laboratory and office to support human mini-heart cardiac disease modeling, drug discovery, and regional cardiovascular clinical innovation BOSTON and SINGAPORE, Sept. 22, 2026 (GLOBE [...]
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
22/09/2026
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision [...]
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
22/09/2026
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential [...]
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
22/09/2026
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic [...]
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
22/09/2026
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a [...]
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
22/09/2026
Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the termination of a [...]
Lymphatic Malformation Alliance (LMA) Meets with FDA Leadership to Elevate Awareness of Lymphatic Malformations and Advance the Urgent Need for Approved Treatments
22/09/2026
LMA brings patient and physician perspectives to FDA leadership to elevate awareness of lymphatic malformations Patient experience highlights the serious, lifelong burden and significant unmet need LMA calls for greater [...]
SafeSpace Global Secures Up to $11 Million in Financing Capacity to Support Next Phase of Growth
22/09/2026
Multi-year financing framework expands access to growth capital and provides increased financial flexibility as SafeSpace Global KNOXVILLE, Tenn., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: [...]
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
22/09/2026
HepaRegeniX to seamlessly advance darizmetinib’s clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage [...]
Transactions in connection with share buy-back program
22/09/2026
Company announcement no. 36 - 26 22 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Bavarian Nordic – Notification of Holding of Treasury Shares
22/09/2026
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares amounted to 3,965, [...]
AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson’s UK to explore sleep-based approaches for Parkinson's disease
22/09/2026
MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson's disease by targeting restorative sleep mechanisms Parkinson's UK-funded research with University College London ( [...]
Dialybrid secures €15 million series A round and announces successful first-in-human implant of novel Silkothane® Arteriovenous Graft for vascular access in hemodialysis
22/09/2026
Silkothane® Arteriovenous Graft is a novel hybrid arteriovenous graft engineered to integrate into patients’ vessels and provide a safe, easy-to-cannulate, durable, vascular access for hemodialysis in patients with end- [...]
Opterion Health Announces Positive Phase 1 Results for OPT101, Supporting Advancement to Phase 2a
22/09/2026
SPARC study achieved all its objectives, establishing a strong clinical foundation for a differentiated, non-glucose-based treatment for peritoneal dialysis Positive Phase 1 results strengthen confidence in OPT101 , [...]
HighLife Raises $90+ Million to start its US Pivotal Study and accelerate Commercial Expansion in Europe
22/09/2026
Paris, France, September 22 – HighLife SAS, a MedTech company focused on transcatheter solutions for structural heart disease, today announced the successful completion of a $90+ Million (€80 Million) financing round . [...]

Pages